At the time of analysis, the ORR was 50% with one complete response in the leiomyosarcoma patient and partial response in one colorectal cancer patient, again showing that tumors harboring ALK fusions/rearrangement are responsive to ALK inhibitors. The gene discussed is ALK; the disease is leiomyosarcoma.